Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Apr 28, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on finding new, easy-to-measure markers in the blood that could help diagnose pancreatic cancer, specifically a type called pancreatic ductal adenocarcinoma (PDAC). This type of cancer is known for being particularly aggressive, with a very low survival rate in the first year after diagnosis. The researchers are using a new technique called the "Modified EXPEL" procedure, which involves collecting and analyzing samples from patients who are already undergoing a common test called endoscopic ultrasound with fine needle aspiration (EUS/FNA). By examining these samples, the goal is to discover specific markers that can indicate the presence of pancreatic cancer without needing to perform more invasive tests.

To participate in this trial, individuals must have a suspicious pancreatic mass and require the EUS/FNA procedure. However, the trial cannot include certain vulnerable groups, such as pregnant women. Those who join the study can expect to have their samples analyzed for potential biomarkers while contributing to important research that may improve cancer diagnostics in the future. This is an exciting opportunity to be part of a study that aims to make diagnosing pancreatic cancer easier and less invasive for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy
• Exclusion Criteria:
• • Vulberable person according to L1121-6 of Public health reglementation in France
• • Pregnant women